Citations

Clear

16 citation(s) found for "Garraway, W M".

Abstract LB390: Genetic risk of prostate cancer: Insights from the Prostate Cancer Sequencing Consortium
Zhang, Yifan , Cheng, Shuyan , Boddicker, Nicholas, Lebo, Matthew , Berry, Alexander S. , Hausler, Ryan , Desai, Heena, Rodriguez, Alex A , Hill, Andrew, Sheng, Xin, Gundell, Susan, Cicek, Mine S., Gignoux, Chris , Garraway, Isla P. , Pasaniuc, Bogdan, Oetjens, Matt, Kibel, Adam S., Kote-Jarai, Zsofia, Couch, Fergus J., Darst, Burcu F., Conti, David V., Haiman, Christopher A., Chen, F Z, Conti, David V. , Conti, David V , Boddicker, Nicholas , Haas, Roni , Dadaev, Tokhir , Desai, Heena , Madduri, Ravi , Sheng, Xin , Lilja, Hans , Melander, Olle , Paşaniuc, Bogdan , Boutros, Paul C. , Oetjens, Matthew T. , Kibel, Adam S. , Klein, Robert J. , Kote‐Jarai, Zsofia , Couch, Fergus J. , Maxwell, Kara N. , Darst, Burcu F. , Haiman, Christopher A.

Mayo Clinic

Cancer Research | April 17, 2026 | Volume: 86 | Issue: 8_Supplement | Pages: LB390-LB390

10.1158/1538-7445.am2026-lb390 Get It

Abstract Inherited susceptibility plays a critical role in prostate cancer (PCa) risk. Using large biobank and case-control datasets, we evaluated the contribution of both common variants and rare germline pathogenic variants (PVs) to overall PCa risk. The Prostate Cancer Exome Sequencing Consortium currently includes 427,388 male participants (51,452 PCa cases and 375,936 controls) with whole-exome sequencing data from ten biobanks and studies: UK Biobank (14,669 cases/195,600 controls), All of Us Research Program (7,577/75,226), African Ancestry Prostate Cancer Consortium (7,176/4,675), Mayo Clinic Biobank (6,031/15,084), Mass General Brigham Biobank (3,393/14,095), Geisinger’s MyCode Community Health Initiative (3,026/15,130), UCLA ATLAS Precision Medicine Biobank (2,850/16,904), Penn Medicine Biobank (2,598/16,255), Colorado Center for Personalized Medicine (2,269/13,399), and Malmo Diet and Cancer (1,863/9,568). Based on self-reported race/ethnicity and estimated genetic ancestry, the cases comprise approximately 79% European, 18% African, and 3% other ancestry populations. Single-variant association analyses tested all variants on chromosomes 1-22 and X with a minor allele count ≥ 5. In gene-based analyses, PVs were defined as rare variants (minor allele frequency [MAF] < 1% in controls) that had either a Variant Effect Predictor (VEP) impact score of “high” or a pathogenic or likely pathogenic ClinVar classification. Associations were estimated using Firth logistic regression, adjusting for age and the top ten genetic principal components. Results from individual studies were combined using fixed-effect meta-analysis. In single-variant association analyses, 496 variants reached genome-wide significance (p<5×10-8; MAF>0.02%). Among these, 458 (92%) variants mapped to previously known risk regions, including three rare PVs in HOXB13 (rs138213197), CHEK2 (rs555607708), and FAM111A (rs533676902). Characterization of the remaining 38 variants is ongoing. Gene-based analyses identified significant associations (p<2.4×10-6) for eight genes: HOXB13 (OR=3.7, 95% CI=3.3-4.2), BRCA2 (OR=2.0, 95% CI=1.7-2.3), CHEK2 (OR=1.6, 95% CI=1.5-1.8), ATM (OR=1.6, 95% CI=1.4-1.9), FAM111A (OR=1.4, 95% CI=1.3-1.5), BIK (OR=1.4, 95% CI=1.2-1.6), SAMHD1 (OR=2.1, 95% CI=1.6-2.7), and SMOC2 (OR=3.2, 95% CI=2.0-5.1). All genes except SMOC2 have been previously implicated in PCa susceptibility. Among cancer predisposition and DNA repair genes, nominal associations were also observed for XRCC2 (OR=1.6, 95% CIs=1.2-2.3) and BRCA1 (OR=1.2, 95% CI=1.0-1.4), whereas the association was not significant for PALB2 (OR=1.2, 95% CI=0.9-1.5). These findings reinforce the role of rare germline PVs, particularly in cancer predisposition and DNA repair genes, in PCa susceptibility. As additional studies are incorporated into the Consortium, we expect this work to provide a more comprehensive characterization of the genetic architecture of PCa. Citation Format: Yifan Zhang, Shuyan Cheng, Nicholas Boddicker, Matthew Lebo, Alexander S. Berry, Roni Haas, Ryan Hausler, Tokhir Dadaev, Heena Desai, Alex A. Rodriguez, Ravi K. Madduri, Andrew Hill, Xin Sheng, Susan M. Gundell, Mine Cicek, Penn Medicine Biobank, Olle Melander, Chris R. Gignoux, Isla P. Garraway, Bogdan Pasaniuc, Paul C. Boutros, Matt Oetjens, Adam S. Kibel, Robert J. Klein, Zsofia Kote-Jarai, Fergus J. Couch, Kara N. Maxwell, Burcu F. Darst, David V. Conti, Christopher A. Haiman, Fei Chen. Genetic risk of prostate cancer: Insights from the Prostate Cancer Sequencing Consortium [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(8_Suppl):Abstract nr LB390.
NCCN Guidelines® Insights: Prostate Cancer Early Detection, Version 1.2023
Moses, Kelvin A. , Sprenkle, Preston C. , Box, Geoffrey N., Carlsson, Sigrid , Catàlona, William J. , Dahl, Douglas M. , Dall’Era, Marc , Davis, John W. , Epstein, Jonathan I. , Etzioni, Ruth B., Farrington, Thomas A., Garraway, Isla P. , Jarrard, David F. , Kauffman, Eric, Kaye, Deborah R. , Kibel, Adam S. , LaGrange, Chad A. , Maroni, Paul, Ponsky, Lee , Salami, Simpa S. , Shaneyfelt, Terrence, Smaldone, Marc C. , Sonn, Geoffrey A. , Tyson, Mark D. , Vapiwala, Neha , Wake, Robert, Washington, Samuel L. , Yu, Alice , Yuh, Bertram, Berardi, Ryan A., Freedman-Cass, Deborah A., Salami, Simpa S , Bahler, Clinton D. , Drake, Bettina F. , Etzioni, Ruth B., Reys, Brian D. , Sánchez, Alejandro , Seibert, Tyler M.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 10, 2023 | Volume: 21 | Issue: 3 | Pages: 236-246

10.6004/jnccn.2023.0014 | PMID 36898362 Get It

The NCCN Guidelines for Prostate Cancer Early Detection provide recommendations for individuals with a prostate who opt to participate in an early detection program after receiving the appropriate counseling on the pros and cons. These NCCN Guidelines Insights provide a summary of recent updates to the NCCN Guidelines with regard to the testing protocol, use of multiparametric MRI, and management of negative biopsy results to optimize the detection of clinically significant prostate cancer and minimize the detection of indolent disease.
Association of black race with improved outcomes following definitive radiotherapy with androgen deprivation therapy for high-risk prostate cancer: A meta-analysis of eight randomized trials.
Kishan, Amar U. , Romero, Tahmineh , Garraway, Isla P. , Roach, Mack , Pisansky, Thomas M. , Michalski, Jeff M. , Jones, Christopher U. , Feng, Felix Y. , Nickols, Nicholas G. , Mahal, Brandon A. , Dess, Robert T. , Steinberg, Michael L. , Elashoff, David , Dess, Robert T , Rettig, Matthew B. , Lee, W. Robert , Rosenthal, Seth A. , Boutros, Paul C. , Tran, Phuoc T , Sandler, Howard M. , Spratt, Daniel E.

Mayo Clinic

Journal of Clinical Oncology | February 19, 2020 | Volume: 38 | Issue: 6_suppl | Pages: 327-327

10.1200/jco.2020.38.6_suppl.327 Get It

327 Background: Though Black men with prostate cancer are more likely to have aggressive disease features than White men, race-specific differences in initial treatment responses in localized disease remains unknown. Methods: Individual patient data were obtained for 9259 patients (including 1674 [18.1%] Black men and 7585 [81.9%] White men) enrolled on eight randomized controlled trials evaluating definitive radiotherapy (RT) ± short-term or long-term androgen deprivation therapy (STADT and LTADT). The primary endpoints were biochemical recurrence (BCR), distant metastasis (DM), and prostate cancer-specific mortality (PCSM). Fine-Gray subdistribution HR (sHR) models were developed to evaluate the cumulative incidences of all endpoints after stratification by National Comprehensive Cancer Network risk grouping. A meta-analysis was done to estimate pair-wise comparisons of treatments within and between Black and White men, after adjusting for age, Gleason score, clinical T stage, and initial PSA. Results: Black men were more likely to have NCCN high-risk disease at enrollment (656/1674 [39.2%] vs 2506/7585 [33%], p<0.001). However, within the high-risk stratum Black men had lower 10-year rates of BCR (46.1% vs. 50.4%, p=0.02), DM (14% vs. 21.6%, p<0.001), and PCSM (4.9% vs. 9.8%, p<0.001). After adjusting for age and disease characteristics, Black men with high-risk prostate receiving RT+STADT had lower rates of BCR (sHR 0.73, 95% CI 0.62-0.86, p<0.001), DM (sHR 0.64, 95% CI 0.49-0.84, p=0.001) and PCSM (sHR 0.49, 95% CI 0.25-0.95, p=0.04). There were no differences in BCR, DM, or PCSM among men receiving RT+LTADT. The interaction between race and the impact of adding STADT to RT alone on BCR was statistically significant (p=0.003). Conclusions: Black men enrolled on randomized trials with long-term follow-up have higher risk disease at enrollment, but have better BCR, DM, and PCSM outcomes with RT-based therapy compared with White men, particularly with the addition of STADT.
Whole-exome sequencing (WES) of HER2+ metastatic breast cancer (MBC) from patients (pts) treated with prior trastuzumab (T): A correlative analysis of TBCRC003.
Wagle, Nikhil , Richardson, Andrea L. , Forero‐Torres, Andres , Hobday, Timothy J. , Dees, Elizabeth Claire , Nanda, Rita , Rimawi, Mothaffar F. , Barry, William T., Gabriel, Stacey B., Garraway, Levi A. , Krop, Ian E. , Rimawi, Mothaffar , Lin, Nancy U. , Leshchiner, Ignaty , Mayer, Ingrid A. , Wolff, Antonio C. , Winer, Eric P.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 536-536

10.1200/jco.2014.32.15_suppl.536 Get It

Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance)
Mandrekar, Sumithra J. , Laumann, Kristina, Walker, Alison R. , Wang, Eunice S. , Kolitz, Jonathan E. , Powell, Bayard L., Attar, Eyal C. , Bloomfield, Clara D. , Kohlschmidt, Jessica, Mrózek, Krzysztof , Garraway, Levi A. , Jané‐Valbuena, Judit , Baltay, Michele , Tracy, Adam , Marcucci, Guido , Stone, Richard M. , Wang, Eunice S. , Roboz, Gail J. , Desai, Pinkal , Stock, Wendy , Hassane, Duane C. , Larson, Richard A.

Mayo Clinic

Blood Advances | December 19, 2018 | Volume: 2 | Issue: 24 | Pages: 3608-3617

10.1182/bloodadvances.2018023689 | PMID 30567725 Get It

Abstract Novel treatment strategies are needed for older patients with acute myeloid leukemia (AML). This randomized phase 2 trial compared the efficacy and safety of 20 mg/m2 of IV decitabine on days 1 to 10 alone (arm A) with those of 1.3 mg/m2 of subcutaneous bortezomib (arm B) on days 1, 4, 8, and 11 for up to 4 10-day cycles followed by monthly 5-day cycles. Previously untreated AML patients age ≥60 years (excluding those with FLT3 mutations and favorable-risk cytogenetics) without restrictions in performance status (PS) or organ function were eligible. Median age was 72.4 years (range, 60.5-92.3 years); 31 patients (19%) had baseline PS ≥2, 35 (22%) had an antecedent hematological disorder, 58 had (39%) adverse cytogenetics, and 7 (5%) and 23 (14%) had abnormal cardiac or renal function. There were no statistically significant differences in overall survival (OS) or responses between the 2 treatment arms. The overall response rate (complete remission + complete remission with incomplete blood count recovery) was 39% (n = 64), with median OS of 9.3 months. Nineteen responders (31%) underwent allogeneic stem cell transplantation. The most common adverse event was febrile neutropenia, and there were no unexpected toxicities. Adding bortezomib to decitabine did not improve outcomes, but responses were better than those in previous trials using 5-day decitabine cycles. This trial was registered at www.clinicaltrials.gov as #NCT01420926.
Abstract 1286: Targeted deep sequencing of colorectal tumor tissues to study associations of tumor subtypes with germline genetic, lifestyle, and environmental risk factors
Zaidi, Syed Hassan Ejaz , Sun, Wei , Huyghe, Jeroen R. , Grasso, Catherine S. , Connolly, Charles M. , French, Amy J. , Mu, Jasmine, Giannakis, Marios , Quist, Michael J., Brenner, Hermann , Campbell, Peter , Chang‐Claude, Jenny , Ferretti, Vincent , Fuchs, Charles, Gsur, Andrea , Harrison, Tabitha A. , Hoffmeister, Michael , Lee, Stephen , Lemire, Mathieu , Miller, Jessica K. , Pasternack, Danielle, Teney, Cherie, Timms, Lee E., Wheeler, David , Zubair, Niha, Garraway, Levi A. , Hsu, Li, Gallinger, Steven, Thibodeau, Stephen N. , Peters, Ulrike , Trinh, Quang M. , Shinbrot, Eve , Borozan, Ivan , Buchanan, Daniel D. , Campbell, Peter, Chan, Andrew Lung-Tat , Gunter, Marc J. , Huang, Wen‐Yi , Krzyzanowski, Paul M. , Mardis, Elaine R. , Newcomb, Polly A. , Stein, Lincoln , Yung, Christina K. , Ogino, Shuji , Hudson, Thomas J , Hoffmeister, Michael , Harrison, Tabitha A , Brenner, Hermann

Mayo Clinic

Cancer Research | July 31, 2017 | Volume: 77 | Issue: 13_Supplement | Pages: 1286-1286

10.1158/1538-7445.am2017-1286 Get It

Abstract The Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO) in collaboration with the Colorectal Cancer Family Registry (CCFR) aims to identify genetic variants and environmental risk factors that impact colorectal cancer (CRC). Over 30 studies from North America, Europe, and Australia participate in GECCO. These studies have collected clinical, epidemiological, and survival data, as well as blood and tumor biospecimens, for over 80,000 CRC cases and controls. The current study aims to conduct targeted deep sequencing of tumors and matching normal DNA to identify recurrent and novel somatic and germline variants in 4,200 CRC cases. To achieve this goal, an AmpliSeq targeted sequencing panel of 1.12 Mbp was constructed to sequence the coding regions of 190 significantly mutated genes identified from whole exome sequencing datasets generated by the Nurses’ Health Study and Health Professional’s Follow-up Study, and The Cancer Genome Atlas. The panel also covers coding regions of 15 genes with germline high penetrance mutations in CRC, 54 regions to detect CRC-related copy number alterations (CNAs), and microsatellite and homopolymer repeat regions to identify defective DNA mismatch repair. Primers were also included to detect Fusobacterium nucleatum DNA in tumor biopsies, as F. nucleatum is thought to promote CRC carcinogenesis. Sequencing of the DNA libraries on Illumina HiSeq 2500 produced a mean coverage of greater than 500X for tumor DNA and 100X for normal DNA, with &gt;85% of the bases covered at the target at 50x. So far, targeted sequencing of &gt;1,500 DNA samples from CRC tumors and normal tissues has identified recurrent and novel somatic mutations, germline genetic variants, and hypermutation status of the tumors due to defective DNA mismatch repair or pathogenic mutations in the POLE gene. Targeted sequencing has also allowed quantification of the F. nucleatum DNA in tumor biopsies; the results were validated by a multiplex QPCR assay. At the AACR annual meeting, we will present targeted sequencing results generated from the first two GECCO-participating studies (n=1,300 cases). These data will be valuable for future association testing of somatic mutations, CNAs, hypermutation status, and F. nucleatum with germline genetic variants, lifestyle, and environmental risk factors and survival. This large study will allow development of better strategies for diagnosis, treatment, and prevention of CRC. Citation Format: Syed H. Zaidi, Wei Sun, Jeroen Huyghe, Catherine S. Grasso, Quang Trinh, Charles Connolly, Amy French, Jasmine Mu, Marios Giannakis, Eve Shinbrot, Ivan Borozan, Michael J. Quist, Hermann Brenner, Daniel Buchanan, Peter Campbell, Andrew Chan, Jenny Chang-Claude, Vincent Ferretti, Charles Fuchs, Andrea Gsur, Marc Gunter, Tabitha Harrison, Michael Hoffmeister, Wen-Yi Huang, Paul Krzyzanowski, Stephen Lee, Mathieu Lemire, Jessica Miller, Danielle Pasternack, Cherie Teney, Elaine Mardis, Polly Newcomb, Lincoln Stein, Lee Timms, David Wheeler, Christina Yung, Niha Zubair, Levi Garraway, Shuji Ogino, Li Hsu, Steven Gallinger, Stephen Thibodeau, Thomas Hudson, Ulrike Peters. Targeted deep sequencing of colorectal tumor tissues to study associations of tumor subtypes with germline genetic, lifestyle, and environmental risk factors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 1286. doi:10.1158/1538-7445.AM2017-1286
Similar Levels of Urological Symptoms Have Similar Impact on Scottish and American Men—Although Scots Report Less Symptoms
Guess, Harry A., Garraway, W M, Panser, Laurel A., Jacobsen, Steven J. , McKelvie, G. B., Oesterling, Joseph E., Lieber, Michael M., Chute, Christopher G. , Girman, Cynthia J. , Lee, Robert J.

Mayo Clinic

Journal of Urology | June 30, 2017 | Volume: 150 | Issue: 5 Part 2 | Pages: 1701-1705

10.1016/s0022-5347(17)35871-8 | PMID 7692105 Get It

Whole-exome sequencing (WES) predicting two extreme phenotypes of response to VEGF-targeted therapies (VEGF-TT) in patients with metastatic clear cell renal cell carcinoma (mRCC).
Fay, André P. , Murray, Bradley A., Albigès, Laurence , Mickey, Suzanne S, Stanton, Melissa, Garraway, Levi A. , Van Allen, Eliezer M , Signoretti, Sabina , Ho, Thai H. , Hakimi, A Ari , Bellmunt, Joaquim , McDermott, David F. , Atkins, Michael B. , Kwiatkowski, David J. , Choueiri, Toni K.

Mayo Clinic

Journal of Clinical Oncology | February 24, 2017 | Volume: 33 | Issue: 7_suppl | Pages: 422-422

10.1200/jco.2015.33.7_suppl.422 Get It

422 Background: There is significant variability in the response to VEGF-TT in mRCC with no validated predictive biomarkers. We hypothesized that whole exome analysis might identify markers of response and resistance to VEGF-TT in mRCC. Methods: mRCC patients who received first-line sunitinib or pazopanib and were in two extreme phenotypes of response were identified. Extreme responders (ER) were defined as PR or CR for ≥3 years (n=10) and primary refractory patients (PRP) were defined as PD within the first 3 months of therapy (n=10). WES was performed in pre-treatment specimens and established Broad Institute analytical pipelines were utilized to identify point mutations and copy number alterations across the exome. ER (n=4) and PRP (n=4) who were part of TCGA project for clear-cell RCC were included in this analysis. Nonsense, missense and indel mutations in established or novel RCC genes were investigated. Results: IMDC prognostic scores were not significantly different between the two groups. VHL mutations were observed at similar frequency in ER and PRP, overall 57%. Mutations in PBRM1 were identified in 7 ER (50%) vs. 1 PRP (7%) (p=0.03). In addition, mutations in TP53 were only found in PRP (p=0.09). No other gene had mutations that were associated with either response or primary refractory disease (Table). Conclusions: In this pilot study, PBRM1 mutations were associated with extreme response to VEGF-TT. However, this was exploratory, and multivariable analysis was not performed. Analysis of additional patient samples is ongoing to confirm or refute this association. If true it suggests that epigenetic effects of PBRM1 mutation may contribute to response to VEGF-TT in mRCC. [Table: see text]
Abstract 5221: Linking the molecular profile of colorectal tumors to germline genetic and environmental risk factors
Zaidi, Syed Hassan Ejaz , Grasso, Catie, Mu, Jasmine, Giannakis, Marios , Connolly, Charles M. , Brenner, Hermann , Chang‐Claude, Jenny , Du, Mengmeng , Ferretti, Vincent , French, Amy J. , Fuchs, Charles S. , Gallinger, Steven , Garraway, Levi A. , Gsur, Andrea , Harrison, Tabitha A. , Hoffmeister, Michael , Huyghe, Jeroen R. , Lemire, Mathieu , McPherson, John D. , Timms, Lee E., Wheeler, David A. , Zubair, Niha, Thibodeau, Stephen N. , Peters, Ulrike , Shinbrot, Eve , Borozan, Ivan , Campbell, Peter T. , Chan, Andrew T. , Gunter, Marc J. , Hsu, Li , Huang, Wen‐Yi , Mardis, Elaine R. , Newcomb, Polly A. , Stein, Lincoln , Sun, Wei , Trinh, Quang M. , Yung, Christina K. , Ogino, Shuji , Hudson, Thomas J , Hoffmeister, Michael , Harrison, Tabitha A , Brenner, Hermann

Mayo Clinic

Cancer Research | July 26, 2016 | Volume: 76 | Issue: 14_Supplement | Pages: 5221-5221

10.1158/1538-7445.am2016-5221 Get It

Abstract The completion of The Cancer Genome Atlas (TCGA) project for colorectal cancer (CRC) has enabled a new, focused phase of sequencing tumor samples for which genome-wide genetic, epidemiological, clinical and lifestyle data have been collected. By combining somatic mutational profiles with these aforementioned data, we may identify and report effective prevention and treatment approaches for a broader population of individuals. The advent of targeted deep sequencing approaches using DNA obtained from formalin fixed paraffin embedded tissues has made possible the genetic characterization of the large numbers of patients needed to make such an effort relevant. As a first step, we describe a custom gene panel designed from large-scale studies for targeted deep sequencing, and its application to over 4,200 CR tumors, collected by the Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO). This study is designed to identify recurrent somatic mutations and copy number alterations (CNAs) for association testing with germline genetic and lifestyle and environmental risk factors for CRC, and thereby identify relevant approaches to impact cancer prevention. The targeted CRC panel includes 205 genes. Genes were primarily selected as significantly mutated genes identified from the Nurses’ Health Study and Health Professional's Follow-up Study (n = 700), and TCGA (n = 525). We also included 15 genes associated with high penetrance germline mutations and augmented the list to include genes in pathways of somatically altered genes, identified by literature review, from public databases and known to be associated with loss of heterozygosity. For these 205 genes, amplification primers were designed to include all coding regions of transcripts that are listed in the UCSC Genome Browser. For regions with CNAs, the TCGA dataset was analyzed to include regions with greater than or equal to 2 copy focal gains or losses that were found in more than 4 or 3 tumors, respectively. Candidate genes in regions with significant CNAs from the TCGA CRC publication (Nature 2012) were also included. For CNAs, 6 to 12 amplicons were designed for each of the 56 selected regions (32 gains and 24 losses). Additional target regions include: 1) 25 microsatellite loci previously used to identify defective DNA mismatch repair and 212 homoploymer repeats. These include microsatellite loci recommended by the NCI Consensus Panel for identifying MSI; 2) amelogenin (for gender); and 3) Fusobacterium to detect a putative CRC-associated pathogen in tumor biopsies. At the AACR annual meeting, we expect to present results for deep sequencing (∼1,000X) of the first 1,000 CR tumors, including any preliminarily identified pathways and subtypes that may provide the basis for association testing with germline genetic and lifestyle and environmental risk factors needed for inferring better approaches to prevention and treatment of CRC. Citation Format: Syed H. Zaidi, Catie Grasso, Jasmine Mu, Eve Shinbrot, Marios Giannakis, Charles Connolly, Ivan Borozan, Hermann Brenner, Peter Campbell, Andrew Chan, Jenny Chang-Claude, Mengmeng Du, Vincent Ferretti, Amy French, Charles Fuchs, Steven Gallinger, Levi Garraway, Andrea Gsur, Marc Gunter, Tabitha Harrison, Michael Hoffmeister, Li Hsu, Wen-Yi Huang, Jeroen Huyghe, Mathieu Lemire, Elaine Mardis, John McPherson, Polly Newcomb, Lincoln Stein, Wei Sun, Lee Timms, Quang Trinh, David Wheeler, Christina Yung, Niha Zubair, Shuji Ogino, Stephen Thibodeau, Ulrike Peters, Thomas Hudson. Linking the molecular profile of colorectal tumors to germline genetic and environmental risk factors. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 5221.